Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 6,905 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 6,905 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $18.78, for a total value of $129,675.90. Following the sale, the chief executive officer owned 339,392 shares in the company, valued at approximately $6,373,781.76. The trade was a 1.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total transaction of $122,441.16.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.95, for a total transaction of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total value of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total value of $33,469.64.

Bicara Therapeutics Trading Down 2.0%

Shares of NASDAQ:BCAX traded down $0.38 during mid-day trading on Friday, hitting $18.41. 1,190,900 shares of the company traded hands, compared to its average volume of 515,465. The stock has a 50-day moving average price of $16.98 and a two-hundred day moving average price of $16.27. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $20.25. The stock has a market cap of $1.01 billion, a P/E ratio of -8.22 and a beta of -0.78.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, Citigroup began coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating for the company. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $30.25.

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bleakley Financial Group LLC bought a new stake in Bicara Therapeutics in the third quarter worth about $481,000. Cantor Fitzgerald L. P. bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $1,579,000. Artisan Partners Limited Partnership bought a new position in shares of Bicara Therapeutics during the 2nd quarter valued at approximately $3,742,000. Schroder Investment Management Group increased its stake in shares of Bicara Therapeutics by 921.0% during the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock worth $3,951,000 after purchasing an additional 383,681 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ increased its stake in shares of Bicara Therapeutics by 160.9% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock worth $922,000 after purchasing an additional 61,201 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.